Induction of an in vitro reversible hypometabolism through chitosan-based nanoparticles

J Microencapsul. 2011;28(4):229-39. doi: 10.3109/02652048.2011.557746.

Abstract

Objective: Chitosan-based nanoparticles (NPs) were prepared to promote intracellular sustained delivery of the synthetic delta opioid D-Ala(2)-D-Leu(5)-enkephalin (DADLE), prolonging peptide activity and inducing a safe and reversible hypometabolic state.

Materials and methods: NPs were prepared by combining ionotropic gelation and ultrasonication treatment. NP uptake studies and the effects of encapsulated DADLE on HeLa cells proliferation were tested by transmission electron microscopy (TEM) analysis, by immuno-fluorescence and immuno-cytochemistry.

Results: DADLE-loaded NPs are produced with suitable characteristics, a satisfactory process yield (55.4% ± 2.4%) and encapsulation efficiency (64.6% ± 2.1%). NPs are effective in inducing a hypometabolic stasis at a 10(-4) M DADLE concentration. Moreover, as seen from the immunofluorescence study, the effect persists through the recovery period (72 h). Indeed, NPs labelled by anti-enkephalin antibody inside cell nucleus reassert that the in vivo release of the peptide can be prolonged with respect to the case of free peptide supply.

Conclusion: The nanoparticulate drug delivery system described seems to be effective in inducing and prolonging a sort of hibernation-like state in the cells.

MeSH terms

  • Chitosan*
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / pharmacology
  • Drug Carriers / chemistry
  • Drug Carriers / pharmacology*
  • Enkephalin, Leucine-2-Alanine / chemistry
  • Enkephalin, Leucine-2-Alanine / pharmacology*
  • HeLa Cells
  • Humans
  • Nanoparticles*

Substances

  • Delayed-Action Preparations
  • Drug Carriers
  • Enkephalin, Leucine-2-Alanine
  • Chitosan